Robeco Institutional Asset Management B.V. Buys 16,953 Shares of AnaptysBio, Inc. $ANAB

Robeco Institutional Asset Management B.V. purchased a new stake in shares of AnaptysBio, Inc. (NASDAQ:ANAB) during the third quarter, Holdings Channel reports. The firm purchased 16,953 shares of the biotechnology company’s stock, valued at approximately $852,000.

A number of other large investors have also added to or reduced their stakes in ANAB. Persistent Asset Partners Ltd purchased a new position in shares of AnaptysBio in the 2nd quarter worth about $39,000. State of Alaska Department of Revenue purchased a new position in shares of AnaptysBio during the 3rd quarter valued at about $85,000. Group One Trading LLC purchased a new position in shares of AnaptysBio during the 2nd quarter valued at about $140,000. State of Wyoming bought a new stake in AnaptysBio in the 2nd quarter worth approximately $158,000. Finally, ADAR1 Capital Management LLC bought a new stake in AnaptysBio in the 1st quarter worth approximately $205,000.

Insider Buying and Selling at AnaptysBio

In other news, Director Hollings Renton sold 5,000 shares of the stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $49.87, for a total transaction of $249,350.00. Following the completion of the sale, the director owned 10,995 shares of the company’s stock, valued at approximately $548,320.65. This represents a 31.26% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 31.50% of the company’s stock.

AnaptysBio Price Performance

Shares of ANAB stock opened at $48.77 on Tuesday. The stock has a market capitalization of $1.46 billion, a PE ratio of 9.08 and a beta of 0.76. AnaptysBio, Inc. has a 1-year low of $20.18 and a 1-year high of $72.36. The business has a 50-day moving average of $52.70 and a 200 day moving average of $56.21.

AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings results on Monday, September 21st. The biotechnology company reported $5.11 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.46) by $5.57. The business had revenue of $27.49 million for the quarter, compared to analyst estimates of $14.06 million. AnaptysBio had a return on equity of 112.00% and a net margin of 82.37%. During the same period last year, the company earned ($1.30) EPS. Analysts anticipate that AnaptysBio, Inc. will post -1.30 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have issued reports on ANAB. Wall Street Zen lowered AnaptysBio from a “buy” rating to a “hold” rating in a research note on Sunday, October 4th. Scotiabank lowered shares of AnaptysBio to a “hold” rating and set a $70.00 price objective for the company. in a report on Tuesday, August 25th. HC Wainwright reaffirmed a “buy” rating and set a $95.00 target price on shares of AnaptysBio in a report on Tuesday, September 22nd. TD Cowen reduced their target price on shares of AnaptysBio from $75.00 to $70.00 and set a “buy” rating on the stock in a report on Tuesday, August 25th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of AnaptysBio in a research note on Friday, August 7th. Thirteen analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $77.79.

About AnaptysBio

AnaptysBio, Inc is a clinical-stage biotechnology company focused on developing antibody-based medicines for immune-mediated diseases. The company uses its proprietary antibody discovery and engineering platform to identify therapeutics designed to modulate immune-system pathways involved in inflammation and autoimmune disorders.

AnaptysBio’s pipeline has included rosnilimab, an investigational antibody designed to activate the PD-1 immune checkpoint pathway, and imsidolimab, an investigational antibody targeting the interleukin-36 receptor.